Dr. Philippe Ruszniewski on NETTER-1 Study Results

Philippe Ruszniewski, MD
Published: Saturday, Sep 26, 2015



Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase III NETTER-1 study.

The study, which investigated the use of 177-Lu-Dotatate (Lutathera) in patients with inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors (NETs), met its primary endpoint, demonstrating a statistically significant and clinically meaningful increase in progression-free survival for 177-Lu-Dotatate versus a double dose of octreotide (Sandostatin LAR). 

There are not many options for patients with neuroendocrine tumors, so these results are exciting, says Ruszniewski.

<<< View more from the 2015 European Cancer Congress



Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase III NETTER-1 study.

The study, which investigated the use of 177-Lu-Dotatate (Lutathera) in patients with inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors (NETs), met its primary endpoint, demonstrating a statistically significant and clinically meaningful increase in progression-free survival for 177-Lu-Dotatate versus a double dose of octreotide (Sandostatin LAR). 

There are not many options for patients with neuroendocrine tumors, so these results are exciting, says Ruszniewski.

<<< View more from the 2015 European Cancer Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x